Thus, there is an unmet clinical need for novel therapies able to overcome mechanisms of tumor immune evasion and ICI resistance such as poor lymphocyte homing and function, defective tumor interferon gamma (IFNγ) signaling and MHC class I expression, and dysregulation in antigen processing and presentation. Here, IFNG is linked to neoplasm.